About

About

NeuroSense

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases.

NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient.
During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense.

To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases.

We are focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases.
Our research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve our goals.

NeuroSense is currently preparing for a phase 2b/3 clinical trial using PrimeC in patients with ALS. We are also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. Additionally, we are studying the mechanisms of action and relevant biomarkers for these diseases.

Vision

Our vision is to provide remedies for people with fatal diseases, changing the course of their disease, extending their lifespan and enhancing quality of life..

Mission

Our mission is to develop combined therapies for complex diseases, targeting multiple mechanisms in a synergistic manner, whilst utilizing regulatory pathways to bring these drugs to market within short timelines.

NeuroSense Pillars

Community

With a patient-centric approach, NeuroSense strives to be an active part of patient communities.

Collaboration

NeuroSense collaborates with leaders in the scientific field, such as clinicians and scientists, and aims to utilize collaborative work with other cutting-edge technology companies.

Synergism

NeuroSense believes in combined therapeutic strategies for complex neurological diseases, that work synergistically on several pertinent targets.

Inspiration

NeuroSense was born from our acquaintance with the unmet need of patients, who are our true inspiration that motivate us to work tirelessly towards an effective treatment.

NeuroSense in the Community

NeuroSense was established to help alleviate the challenges of patients. For that reason, we are dedicated to raising awareness of the diseases and assisting nonprofit organizations in their fundraising efforts.

NeuroSense in the Community

NeuroSense was established to help alleviate the challenges of patients. For that reason, we are dedicated to raising awareness of the diseases and assisting nonprofit organizations in their fundraising efforts.

In Memoriam

Shay Rishoni

Shay began serving as an Advisory Board member in 2016. He passed away on May 24th 2018.

Shay was Chairman and former CEO at Prize4Life, a non-profit organization dedicated to accelerating the discovery of treatments and a cure for ALS. He received the President’s medal for volunteers in 2016.
Shay held an MBA from the University of Hartford.

Shay was a truly inspiring and optimistic man, who didn’t let his disease stop him from doing amazing work for the ALS community.
We are honored to have known him and worked with him.
He leaves us with an immense legacy.

Join Our Newsletter